Neoplasms

All Conditions

Heart and Blood Diseases

Digestive System Diseases

Symptoms and General Pathology

Rare Diseases

Carcinoma

Hypertension

Carcinoma, Hepatocellular

Hypertension, Portal

Hemorrhage

Varicose Veins

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Acute Graft Versus Host Disease

Anti-Arrhythmia Agents

Antihypertensive Agents

Vasodilator Agents

All Drugs and Chemicals

Propranolol

Adrenergic beta-Antagonists

Adrenergic Agents

Adrenergic Antagonists

Neurotransmitter Agents

Endoscopic treatment alone is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.

endoscopic variceal ligation (EVL) or Gastric Variceal Sclerotherapy (GVS)

Endoscopic treatment alone versus combined propranolol is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.

Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period

propranolol

Ming Chih Hou, MD

Patients with hepatocellular carcinoma and esophageal varices bleeding were randomized to undergo endoscopic ligation alone (group A) and additive propranolol treatment (group B) after stabilization of their first acute bleeding.

Esophageal variceal bleeding is characteristic of high rebleeding rate and mortality. Thanks to the recent advance of treatment for variceal bleeding such as non-selective beta blocker (NSBB) added to endoscopic ligation further reduce rebleeding in cirrhotic patients, the rebleeding rate and mortality has a marked reduction. However, hepatocellular carcinoma (HCC) is a distinct group characteristic of very poor prognosis in patients with portal hypertension when compared to those of liver cirrhosis only. Therefore, the investigators design a study to randomize patients with HCC and acute variceal bleeding to endoscopic treatment alone and combination with endoscopic treatment and NSBB. This is the two years study.

A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC)

Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma

Taipei Veterans General Hospital, Taiwan

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC)	NCT01451658	Gastroesophagea... Hepatocellular ...	propranolol	18 Years - 80 Years	Taipei Veterans General Hospital, Taiwan
A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC)	NCT01451658	Gastroesophagea... Hepatocellular ...	propranolol	18 Years - 80 Years	Taipei Veterans General Hospital, Taiwan
A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC)	NCT01451658	Gastroesophagea... Hepatocellular ...	propranolol	18 Years - 80 Years	Taipei Veterans General Hospital, Taiwan

Spots Global Cancer Trial Database for rebleeding

Every month we try and update this database with for rebleeding cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for rebleeding

Every month we try and update this database with for rebleeding cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for rebleeding cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.